NUC-7738: The Caterpillar Fungus Drug in an Early Cancer Trial

Facebook ↗WhatsApp ↗

Originally published 2021-10-14.

NUC-7738 and Early Cancer-Drug Research

NUC-7738 is an experimental cancer drug built from cordycepin, a natural molecule associated with the so-called caterpillar fungus. In October 2021, researchers at the University of Oxford and the British company NuCana reported that a re-engineered version of that molecule was far stronger against cancer cells in the lab than the natural compound, and that it showed early hints of activity in a small first-in-human trial.

The short answer for anyone searching this topic: it is a promising lead, not a cure. Phase 1 trials exist mainly to test safety and dosing, and the people treated had advanced cancers that had stopped responding to standard care. The interesting part is the chemistry behind it, which explains why scientists bothered to redesign a molecule they had known about for decades.

What the Oxford team reported

The work was published in the journal Clinical Cancer Research in September 2021. Laboratory experiments compared NUC-7738 with plain cordycepin across a range of cancer cell lines. According to the university, the modified drug was up to 40 times more potent at killing cancer cells than the parent compound.

Alongside the lab work came the first clinical data, from a Phase 1 study called NuTide:701. It enrolled a small group of patients, reported as 28, with advanced solid tumours whose disease had progressed after the usual treatments. The authors described the drug as well tolerated at the doses tested and wrote of "encouraging signals of anti-tumour activity and prolonged disease stabilization" in some patients.

That phrase is careful on purpose. "Disease stabilisation" means some tumours stopped growing for a while; it does not mean they disappeared. In a trial without a comparison group, nobody can yet say how much of that was due to the drug.

From a Himalayan fungus to a lab-made drug

Ophiocordyceps sinensis is a parasitic fungus that infects the larvae of ghost moths living in high grasslands of the Tibetan Plateau and the Himalaya. The fungus kills its host underground and sends a thin stalk up through the soil, which is why it is called caterpillar fungus, or yartsa gunbu ("summer grass, winter worm") in Tibetan. It has been prized for centuries in traditional Tibetan and Chinese medicine and can sell for very high prices, which has made harvesting an important source of income in parts of the region.

Cordycepin, chemically known as 3'-deoxyadenosine (often shortened to 3'-dA), is usually associated with this group of fungi. It was first isolated in the early 1950s from a close relative, Cordyceps militaris, which is easier to cultivate and is widely used as a source of the compound; cordycepin can now also be made synthetically. So the "Himalayan fungus" headline is a little romantic: the drug is made in a laboratory and does not depend on wild harvesting at all.

Cordycepin looks almost exactly like adenosine, one of the building blocks of RNA. Cells mistake it for the real thing, and once it is incorporated it can disrupt the way they make and process genetic messages. That is attractive against cancer cells, which grow and divide quickly.

Why natural cordycepin never became a cancer drug

If cordycepin has been studied since the 1950s, why is it not already a standard treatment? The Oxford paper set out three practical obstacles:

  • It is destroyed quickly. An enzyme in the blood, adenosine deaminase, breaks cordycepin down within minutes, so very little reaches a tumour.
  • It needs a doorway. To get into a cell, cordycepin relies on a transporter protein in the cell membrane, and many cancers make little of it.
  • It needs activating. Inside the cell, an enzyme has to attach a phosphate group before the molecule can act. Some cancer cells are poor at this step.

Each of these is a way for tumours to escape. A drug that only works when all three conditions are favourable is not much use in patients.

How the ProTide redesign works

NuCana's approach, called ProTide technology, attaches a small chemical "cap" to the molecule. The cap protects it from adenosine deaminase in the bloodstream, lets it slip into cells without needing the transporter, and delivers it already carrying the phosphate group it needs. Once inside, the cell's own enzymes remove the cap and release the active form.

The ProTide idea is not new to medicine. It was developed by chemists at Cardiff University and is used in established antiviral medicines, including the hepatitis C drug sofosbuvir and the HIV drug tenofovir alafenamide. Applying it to an old anticancer molecule was the novel step. The researchers wrote that their results supported further clinical evaluation of NUC-7738 "as a novel cancer treatment".

What Phase 1 results can and cannot tell you

Drug development usually moves through several stages. Phase 1 trials involve small numbers of people and focus on safety, side effects and the right dose. Phase 2 looks more closely at whether the drug works in specific cancers. Phase 3 compares it with the existing standard in large groups of patients. Many compounds that look good in Phase 1 fall away later, either because the benefit is too small or because side effects appear in larger groups.

So it helps to read news of a "potent cancer killer" with a few questions in mind:

  • Was the result in cells, in animals or in people?
  • How many patients were treated, and was there a comparison group?
  • Did tumours shrink, or did they simply stop growing for a period?
  • Has the work been published in a peer-reviewed journal, and has the company since reported later-stage results?

For NUC-7738, the 2021 answers were: lab cells plus a small, uncontrolled first-in-human study, published in a peer-reviewed journal. Phase 2 work was planned with NuCana, and at the ESMO congress in 2022 the team reported Phase 1 data from 38 patients, with the drug generally well tolerated and signs of prolonged stable disease, particularly in melanoma, but no response rates given. Anyone following the drug today should check the company's announcements or a trial registry such as ClinicalTrials.gov for the current status.

Common myths about caterpillar fungus and cancer

Myth: eating cordyceps supplements gives you the same effect. It does not. The trial used a chemically modified drug given under medical supervision. Natural cordycepin is broken down rapidly in the body, which is the whole reason the redesign was needed. Supplements sold as cordyceps also vary widely in what they actually contain.

Myth: a natural origin means a drug is gentle. Many powerful chemotherapy drugs, such as paclitaxel from the Pacific yew tree, began as natural compounds. Origin says nothing about safety; only trials can.

Myth: an early trial means a treatment is around the corner. Even successful drugs typically take years to pass through Phase 2 and Phase 3. Anyone living with cancer who is curious about experimental options should talk to their doctor, who can explain which trials might be suitable and safe.

The wider picture in 2021

The NUC-7738 news arrived at a time when other cancer research was also making headlines. Around the same period, researchers reported that some patients with advanced head and neck cancer who received immunotherapy, which helps the body's immune system recognise and attack tumour cells, were still alive years after they had been expected to die from the disease. Immunotherapy has changed treatment for several cancers, although it does not work for everyone and can cause its own serious side effects.

Taken together, these stories show two routes modern oncology is exploring: smarter chemistry that gets old molecules past a tumour's defences, and treatments that recruit the immune system. Both depend on slow, careful trials before they reach routine care.

Sources: Schwenzer et al., Clinical Cancer Research (2021), doi:10.1158/1078-0432.CCR-21-1652; University of Oxford, 8 October 2021: Anti-cancer drug derived from fungus shows promise in clinical trials; ScienceAlert, 11 October 2021; ESMO Congress 2022, Abstract 455MO: NuTide:701 Phase I results; Wikipedia: Ophiocordyceps sinensis; Wikipedia: Cordycepin; ClinicalTrials.gov.

COMMENTS